Download the full article (PDF) Introduction Antibodies are cornerstone molecules of adaptive immunity and have become central to therapeutic and diagnostic biotechnology. Classical antibodies (e.g., human IgG) comprise two heavy and two light chains, forming a complex quaternary structure that delivers high-affinity, high-specificity binding to antigens. However, in the 1990s, researchers discovered that members […]
Download the full article (PDF) Introduction Antibodies are cornerstone molecules of adaptive immunity and have become central to therapeutic and diagnostic biotechnology. Classical antibodies (e.g., human IgG) comprise two
Download the full article (PDF) Introduction The landscape of targeted cancer therapy has expanded dramatically with the advent of sophisticated small-molecule modalities capable of modulating oncogenic proteins through mechanisms
Download the full article (PDF) Introduction Antibody oligonucleotide conjugates (AOCs) represent an emerging class of biotherapeutics that combine the cell-targeting precision of antibodies with the gene-modulating capabilities of oligonucleotides. Structurally,
Download the full article (PDF) Introduction Immunocytokines, which are fusion proteins combining a cytokine with an antibody or antibody fragment, constitute a rapidly advancing class of targeted immunotherapeutics. They
Introduction Cell-based high throughput screening (HTS) platforms have significantly accelerated drug discovery by providing high-content, scalable, and clinically relevant data early in the screening pipeline. Cell-based assays have become indispensable
The landscape of cancer immunotherapy is rapidly evolving with the emergence of several cutting-edge modalities. Some examples include genetically engineered chimeric antigen receptor (CAR) immune cell subsets, neoantigen vaccines
Introduction Degrader Antibody Conjugates (DACs) represent a revolutionary therapeutic modality that combines the precision of monoclonal antibodies (mAbs) with the potent protein degradation capabilities of targeted protein degraders, such as
With 30+ years of expertise in cell-based potency assay development, we provide accurate, GMP-compliant assays for AAV vectors and gene therapy candidates, ensuring a faster path to clinical success. Click
Press Release | Marin Biologic Labs Achieves Flawless FDA Inspection for Second Consecutive Year, Expands Biopharmaceutical Services What are PROTACs? Proteolysis Targeting Chimeric (PROTAC) drugs are innovative molecules that utilize
What is a Cell Based Assay? A cell based assay uses live cells to quantify biological processes and evaluate cellular responses to various stimuli. These assays provide a more physiologically
